Table 1. CLL patient treatment and subclonal responses at relapse.
| Tumor | 1st Treatment | Response | 2nd Treatment | Response | Clonal Response |
|---|---|---|---|---|---|
| CLL2 | Clb | PR | Flu | NR | Stable |
| CLL3 | FC | PR | Campath | PR | Selection with evolution |
| CLL4 | FC | CR | Ibrutinib | PR | Selection |
| CLL6 | FC | PR | − | − | Stable |
| CLL8 | Flu | PR | SCT | CR | Stable |
| CLL13 | Clb | PR | Clb | PR | Selection |
| CLL14 | Clb | CR | Clb | NR | Selection |
| CLL16 | Flu | PR | SCT | CR | Selection with evolution |
| CLL18 | Clb | CR | − | − | Selection with evolution |
| CLL19 | FC | CR | Campath | CR | Stable |
| CLL32 | FC | PR | FCR | PR | Selection |
Paired pre-treatment and relapse samples of 11 patients were analyzed by multiplexed-FISH. Clonal response was determined by comparison of the subclonal architecture between pre-treatment and relapse samples. A ≥15% increase in a subclone size was considered indicative of clonal selection.
Note: Bold text indicates the treatment administered preceding the analysed relapse sample; Clb, chlorambucil; FC(R), fludarabine cyclophosphamide (rituximab); Flu, fludarabine; SCT, stem cell transplant; NR, no response; PR, partial response; CR, complete response.